logo-loader
viewNew Guinea Energy Ltd

New Guinea Energy's sale approval puts it among leading % Gainers

au_share_price_up350_54e3ebcfa5625.jpg

Wednesday's leading ASX % Gainers intra-day.

New Guinea Energy's (ASX:NGE) wholly owned subsidiary Kirkland Limited has received notification that the final condition precedent for the sale of its 50% interest in Petroleum Prospecting Licence (PPL) 269 to Barracuda Limited has been met.

Barracuda is a subsidiary of Santos (ASX:STO).

The Minister for Petroleum and Energy has advised his approval of the Instrument of Transfer of the 50% from Kirkland to STO.

CompanyCodeLastChangeTradesVolume
Water Resources Group WRG $0.002 100% 7 1,469,259
New Guinea Energy NGE $0.015 87.50% 68 7,715,864
Mesa Minerals MAS $0.015 50% 1 250,000
Bass Metals BSM $0.003 50% 1 180,000
Toll Holdings TOL $8.930 46.88% 4927 23,153,906
Dynast Resources DMA $0.020 42.86% 2 55,000
Delecta Ltd DLC $0.007 40% 4 1,513,688
American Patriot Oil AOW $0.175 34.62% 11 132,986
Rectifier Technology RFT $0.004 33.33% 2 129,988
Avalon Minerals AVI $0.032 28% 5 82,546
Patrys Ltd PAB $0.014 27.27% 84 11,588,291

 

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: New Guinea Energy Ltd

Price: 0.5 AUD

ASX:NGE
Market: ASX
Market Cap: $18.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Medexus Pharmaceuticals sees record revenue and more strong growth beyond 1Q...

Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:PDDPF) CEO Ken d’Entremont tells Proactive the specialty pharmaceutical company posted record revenue of C$27.5 million during its fiscal first-quarter thanks to strong sales of its four leading drug products. d’Entremont says he sees because the...

26 minutes ago

2 min read